Stockreport

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders [Yahoo! Finance]

RenovoRx, Inc.  (RNXT) 
PDF RenovoCath Gaining Validation in an Initial U.S. Market Estimated at $400 Million Annually MOUNTAIN VIEW, Calif., February 26, 2025 BUSINESS WIRE RenovoRx, Inc . ("Re [Read more]